- Home
- IPEX vs UNCY Comparison
IPEX vs UNCY Comparison
Compare IPEX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPEX | UNCY |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.5M | 126.4M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IPEX | UNCY |
|---|---|---|
| Price | $10.28 | $5.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 39.0K | ★ 358.3K |
| Earning Date | 04-15-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $3.71 |
| 52 Week High | $10.40 | $11.00 |
Technical Indicators
Market Signals| Indicator | IPEX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.37 |
| Support Level | N/A | $5.35 |
| Resistance Level | N/A | $6.95 |
| Average True Range (ATR) | 0.00 | 0.37 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 0.00 | 31.35 |
Price Performance
Historical ComparisonAbout IPEX Inflection Point Acquisition Corp. V Class A Ordinary Shares
Inflection Point Acquisition Corp V is a blank check company.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.